Skip to main content

Table 1 Baseline patient and disease characteristics by patient status and country

From: The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe

 

Outpatients

Inpatients

Argentina

Hungary

Mexico

Peru

Poland

Total

Argentina

Hungary

Mexico

Peru

Poland

Total

N = 75

N = 75

N = 75

N = 101

N = 75

N = 401

N = 75

N = 81

N = 77

N = 78

N = 75

N = 386

Gender, male, n (%)

40 (53.3)

33 (44.0)

31 (41.3)

58 (57.4)

41 (54.7)

203 (50.6)

46 (61.3)

45 (55.6)

39 (50.6)

43 (55.1)

46 (61.3)

219 (56.7)

Age, years, mean (SD)

3.8 (2.4)

4.4 (2.0)

3.0 (3.2)

3.3 (3.3)

3.9 (2.6)

3.6 (2.8)

2.9 (2.2)

3.7 (2.1)

2.6 (3.5)

2.4 (3.4)

4.2 (2.3)

3.1 (2.8)

Race, n (%)

 Caucasian

4 (5.3)

75 (100)

2 (2.7)

–

75 (100)

156 (38.9)

7 (9.3)

81 (100)

3 (3.9)

2 (2.6)

75 (100)

168 (43.5)

 Hispanic/Latino

71 (94.7)

–

61 (81.3)

90 (89.1)

–

222 (55.4)

68 (90.7)

–

69 (89.6)

46 (59.0)

–

183 (47.4)

 Latino/Mestizo/Indigenous

–

–

12 (16.0)

11 (10.9)

–

23 (5.7)

–

–

5 (6.5)

30 (38.5)

–

35 (9.1)

Area of residence, n (%)

 Rural

4 (5.3)

4 (5.3)

13 (17.3)

4 (4.0)

7 (9.3)

32 (8.0)

12 (16.0)

28 (34.6)

16 (20.8)

23 (29.5)

23 (30.7)

102 (26.4)

 Urban

70 (93.3)

71 (94.7)

62 (82.7)

97 (96.0)

64 (85.3)

364 (90.8)

62 (82.7)

53 (65.4)

61 (79.2)

55 (70.5)

51 (68.0)

282 (73.1)

 Not available

1 (1.3)

–

–

–

4 (5.3)

5 (1.2)

1 (1.3)

–

–

–

1 (1.3)

2 (0.5)

Maximum number of skin lesions, n (%)

  < 50

20 (26.7)

51 (68.0)

27 (36.0)

56 (55.4)

25 (33.3)

179 (44.6)

3 (4.0)

2 (2.5)

20 (26.0)

1 (1.3)

18 (24.0)

44 (11.4)

 50–249

36 (48.0)

16 (21.3)

44 (58.7)

35 (34.7)

36 (48.0)

167 (41.6)

50 (66.7)

59 (72.8)

45 (58.4)

7 (9.0)

37 (49.3)

198 (51.3)

 250–500

17 (22.7)

7 (9.3)

4 (5.3)

9 (8.9)

14 (18.7)

51 (12.7)

14 (18.7)

20 (24.7)

11 (14.3)

50 (64.1)

12 (16.0)

107 (27.7)

  > 500

2 (2.7)

1 (1.3)

–

1 (1.0)

–

4 (1.0)

8 (10.7)

–

1 (1.3)

20 (25.6)

8 (10.7)

37 (9.6)

Immuno-compromised, yes, n (%)a

1 (1.3)

–

1 (1.3)

–

–

2 (0.5)

1 (1.3)

4 (4.9)

5 (6.5)

1 (1.3)

–

11 (2.8)

  1. SD Standard Deviation
  2. aPatients were considered immunocompromised if they had ≥1 of the following conditions: HIV/AIDS, congenital immunodeficiency, received systemic steroids, or had any other immunocompromised condition listed in their medical history
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us